45
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What are the long-term health outcomes associated with COVID-19 infection 1 year after hospital discharge?

          Findings

          In this cohort study of 2433 patients who had been hospitalized with COVID-19, the most common symptoms at 1 year after discharge were fatigue, sweating, chest tightness, anxiety, and myalgia. Patients with severe disease had more postinfection symptoms and higher chronic obstructive pulmonary disease assessment test scores.

          Meaning

          This study reported prolonged symptoms of COVID-19 and found that severe disease during hospitalization was a risk factor for more symptoms and higher chronic obstructive pulmonary disease assessment test scores.

          Abstract

          This cohort study investigates 1-year health outcomes and their associated risk factors among COVID-19 survivors in Wuhan, China.

          Abstract

          Importance

          The long-term health outcomes and symptom burden of COVID-19 remain largely unclear.

          Objective

          To evaluate health outcomes of COVID-19 survivors 1 year after hospital discharge and to identify associated risk factors.

          Design, Setting, and Participants

          This retrospective, multicenter cohort study was conducted at 2 designated hospitals, Huoshenshan Hospital and Taikang Tongji Hospital, both in Wuhan, China. All adult patients with COVID-19 discharged between February 12 and April 10, 2020, were screened for eligibility. Of a consecutive sample of 3988 discharged patients, 1555 were excluded (796 declined to participate and 759 were unable to be contacted) and the remaining 2433 patients were enrolled. All patients were interviewed via telephone from March 1 to March 20, 2021. Statistical analysis was performed from March 28 to April 18, 2021.

          Exposures

          COVID-19.

          Main Outcomes and Measures

          All patients participated in telephone interviews using a series of questionnaires for evaluation of symptoms, along with a chronic obstructive pulmonary disease (COPD) assessment test (CAT). Logistic regression models were used to evaluate risk factors for fatigue, dyspnea, symptom burden, or higher CAT scores.

          Results

          Of 2433 patients at 1-year follow-up, 1205 (49.5%) were men and 680 (27.9%) were categorized into the severe disease group as defined by the World Health Organization guideline; the median (IQR) age was 60.0 (49.0-68.0) years. In total, 1095 patients (45.0%) reported at least 1 symptom. The most common symptoms included fatigue, sweating, chest tightness, anxiety, and myalgia. Older age (odds ratio [OR], 1.02; 95% CI, 1.01-1.02; P < .001), female sex (OR, 1.27; 95% CI, 1.06-1.52; P = .008), and severe disease during hospital stay (OR, 1.43; 95% CI, 1.18-1.74; P < .001) were associated with higher risks of fatigue. Older age (OR, 1.02; 95% CI, 1.01-1.03; P < .001) and severe disease (OR, 1.51; 95% CI, 1.14-1.99; P = .004) were associated with higher risks of having at least 3 symptoms. The median (IQR) CAT score was 2 (0-4), and a total of 161 patients (6.6%) had a CAT score of at least 10. Severe disease (OR, 1.84; 95% CI, 1.31-2.58; P < .001) and coexisting cerebrovascular diseases (OR, 1.95; 95% CI, 1.07-3.54; P = .03) were independent risk factors for CAT scores of at least 10.

          Conclusions and Relevance

          This study found that patients with COVID-19 with severe disease during hospitalization had more postinfection symptoms and higher CAT scores.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

          The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial increase in hospitalizations for pneumonia with multiorgan disease. This review discusses current evidence regarding the pathophysiology, transmission, diagnosis, and management of COVID-19.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

            Background The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the associated risk factors, in particular disease severity. Methods We did an ambidirectional cohort study of patients with confirmed COVID-19 who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7, 2020, and May 29, 2020. Patients who died before follow-up, patients for whom follow-up would be difficult because of psychotic disorders, dementia, or re-admission to hospital, those who were unable to move freely due to concomitant osteoarthropathy or immobile before or after discharge due to diseases such as stroke or pulmonary embolism, those who declined to participate, those who could not be contacted, and those living outside of Wuhan or in nursing or welfare homes were all excluded. All patients were interviewed with a series of questionnaires for evaluation of symptoms and health-related quality of life, underwent physical examinations and a 6-min walking test, and received blood tests. A stratified sampling procedure was used to sample patients according to their highest seven-category scale during their hospital stay as 3, 4, and 5–6, to receive pulmonary function test, high resolution CT of the chest, and ultrasonography. Enrolled patients who had participated in the Lopinavir Trial for Suppression of SARS-CoV-2 in China received severe acute respiratory syndrome coronavirus 2 antibody tests. Multivariable adjusted linear or logistic regression models were used to evaluate the association between disease severity and long-term health consequences. Findings In total, 1733 of 2469 discharged patients with COVID-19 were enrolled after 736 were excluded. Patients had a median age of 57·0 (IQR 47·0–65·0) years and 897 (52%) were men. The follow-up study was done from June 16, to Sept 3, 2020, and the median follow-up time after symptom onset was 186·0 (175·0–199·0) days. Fatigue or muscle weakness (63%, 1038 of 1655) and sleep difficulties (26%, 437 of 1655) were the most common symptoms. Anxiety or depression was reported among 23% (367 of 1617) of patients. The proportions of median 6-min walking distance less than the lower limit of the normal range were 24% for those at severity scale 3, 22% for severity scale 4, and 29% for severity scale 5–6. The corresponding proportions of patients with diffusion impairment were 22% for severity scale 3, 29% for scale 4, and 56% for scale 5–6, and median CT scores were 3·0 (IQR 2·0–5·0) for severity scale 3, 4·0 (3·0–5·0) for scale 4, and 5·0 (4·0–6·0) for scale 5–6. After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80–3·25) for scale 4 versus scale 3 and 4·60 (1·85–11·48) for scale 5–6 versus scale 3 for diffusion impairment; OR 0·88 (0·66–1·17) for scale 4 versus scale 3 and OR 1·77 (1·05–2·97) for scale 5–6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58–0·96) for scale 4 versus scale 3 and 2·69 (1·46–4·96) for scale 5–6 versus scale 3 for fatigue or muscle weakness. Of 94 patients with blood antibodies tested at follow-up, the seropositivity (96·2% vs 58·5%) and median titres (19·0 vs 10·0) of the neutralising antibodies were significantly lower compared with at the acute phase. 107 of 822 participants without acute kidney injury and with estimated glomerular filtration rate (eGFR) 90 mL/min per 1·73 m2 or more at acute phase had eGFR less than 90 mL/min per 1·73 m2 at follow-up. Interpretation At 6 months after acute infection, COVID-19 survivors were mainly troubled with fatigue or muscle weakness, sleep difficulties, and anxiety or depression. Patients who were more severely ill during their hospital stay had more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, and are the main target population for intervention of long-term recovery. Funding National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Key Research and Development Program of China, Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis, and Peking Union Medical College Foundation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

              Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. However, information on cardiac injury in patients affected by COVID-19 is limited.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                29 September 2021
                September 2021
                29 September 2021
                : 4
                : 9
                : e2127403
                Affiliations
                [1 ]Department of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China
                [2 ]Department of General Surgery, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China
                [3 ]Wuhan Huoshenshan Hospital, Wuhan, China
                [4 ]Department of Orthopedics, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China
                [5 ]Pulmonary and critical care medicine center, Chinese PLA Respiratory Disease Institute, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China
                [6 ]Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China
                [7 ]Institute of Cancer, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China
                [8 ]Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China
                [9 ]Department of Biochemistry and Molecular Biology, Third Military Medical University (Army Medical University), Chongqing, China
                [10 ]Institute of Infection and Immunology, University of London, London, United Kingdom
                [11 ]Department of Epidemiology, College of Preventive Medicine, Third Military Medical University (Army Medical University), Chongqing, China
                [12 ]Department of Medical and Research Management, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China
                [13 ]Wuhan Taikang Tongji Hospital, Wuhan, China
                Author notes
                Article Information
                Accepted for Publication: July 17, 2021.
                Published: September 29, 2021. doi:10.1001/jamanetworkopen.2021.27403
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Zhang X et al. JAMA Network Open.
                Corresponding Authors: Li Li, MD, Professor, Department of Respiratory Medicine ( dpyyhxlili@ 123456tmmu.edu.cn ), and Lixia Cheng, MS, Department of Medical Quality Management ( clx109@ 123456tmmu.edu.cn ), Daping Hospital, Army Medical University, Chongqing 400042, China.
                Author Contributions : Dr Li and L. Cheng had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Mss Zhang and F. Wang and Dr Shen contributed equally to this work.
                Concept and design: Shen, Liu, He, Cao, Cheng, Li.
                Acquisition, analysis, or interpretation of data: Xue Zhang, F. Wang, Shen, Xiao-Hua Zhang, Cen, B. Wang, Zhao, Zhou, Hu, M. Wang, Miao, Jones, Ma, Cao, Cheng, Li.
                Drafting of the manuscript: Xue Zhang, F. Wang, Shen, Xiao-Hua Zhang, Cen, B. Wang, Zhou, Hu, M. Wang, He, Cao, Cheng, Li.
                Critical revision of the manuscript for important intellectual content: Shen, Zhao, Liu, Miao, Jones, Ma, Li.
                Statistical analysis: F. Wang, Shen, Zhao, Ma.
                Obtained funding: Ma, Cheng, Li.
                Administrative, technical, or material support: Shen, Liu.
                Supervision: Shen.
                Conflict of Interest Disclosures: Dr Jones reported personal fees from GlaxoSmithKline Employee and stocks and shares from GlaxoSmithKline outside the submitted work. No other disclosures were reported.
                Funding/Support: This work was supported by the National Natural Science Foundation of China (81672287), the Joint Scientific Research Project of the Chongqing Health Commission and the Science and Technology Commission (2020FYYX213),the Outstanding Youth Science Fund of Chongqing (cstc2020jcyjjqX0014), Chongqing Talent Fund (CQYC202005003) and by the Science Foundation for Outstanding Young People of the Army Medical University.
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Article
                zoi210799
                10.1001/jamanetworkopen.2021.27403
                8482055
                34586367
                70a6a3b5-e94d-459c-85db-3eb0a9204b20
                Copyright 2021 Zhang X et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 13 May 2021
                : 17 July 2021
                Categories
                Research
                Original Investigation
                Online Only
                Global Health

                Comments

                Comment on this article